344079-M

Flurbiprofen

A mixture of S(+) and R(-) enantiomers.

• Synonim(y): Flurbiprofen, (±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
• Wzór empiryczny (zapis Hilla): C₁₅H₁₃FO₂
• Numer CAS: 5104-49-4
• Masa cząsteczkowa: 244.26
• UNSPSC Code: 12352200
• MDL number: MFCD00079303
• Assay: ≥98% (HPLC)
• Form: solid
• Storage condition: OK to freeze

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze
• color: white
• solubility: DMSO: 50 mg/mL
• storage temp.: 10-30°C
• InChI: 1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
• InChI key: SYTBZMRGLBWNTM-UHFFFAOYSA-N

Opis

General description

A mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.

A mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice

Biochem/physiol Actions

Primary Target
Cyclooxygenase

Target IC₅₀: 5 nM for LPS-induced COX

Preparation Note

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.

Other Notes

Jantzen, P.T., et al. 2002. J. Neurosci.22, 2246.
Hinz, R., et al. 2001. Pharmacol. Res.18, 151.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Range, S.P., et al. 2000. Eur. Respir. J.15, 751.
van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther.16, 353.
Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther.282, 339.
Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol.75, 1088.
Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Toxic & Carcinogenic / Teratogenic (G)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS06
• signalword: Danger
• hcodes: H301
• pcodes: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral
• Klasa składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable